This is broadly in line with an Asian retrospective cohort study of patients with advanced NSCLC, in which 88% of the patients with EGFR Mut + NSCLC received a TKI at some point in their treatment (first-, second-, or third-line) [15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.